Status: Recruiting
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
Participants needed: 10
Trial details
Phase: Phase 1Age: 20-80Biological sex: AllType: InterventionalSponsor: Taiwan Bio Therapeutics Inc.Updated: Jun 6, 2025Locations: 1
Eligibility criteria
Patents, with age ≤20 or ≤80 years old. [+5]
Age < 20 or >80 years old. [+15]